Eric Rowinsky, MD

Dr. Rowinsky is a medical oncologist with significant experience in developing impactful oncology drugs. He was a lead clinical investigator on early developmental studies on many classes of targeted therapeutics including erlotinib, gefitinib, panitumumab, temsirolimus, ridaforolimus, and trabectedin. Dr. Rowinsky was also Chief Medical Officer at ImClone Systems, leading the team that achieved approval of cetuximab, ramucirumab and necitumumab. In addition, he has performed seminal clinical development and pharmacologic studies for paclitaxel, docetaxel, irinotecan and topotecan. Currently he serves on the board of directors for Biogen, Verastem and Purple Biotech.